Cruise is now cruising some Houston streets. The self-driving car service has launched with $5 flat-rate rides. Photo courtesy of Cruise

For the first time, Houstonians can hail an autonomous vehicle to get from point A to point B, thanks to a tech company's latest market roll out.

San Francisco-based Cruise, which has launched in its hometown, Phoenix, and Austin over the past year and a half, previously announced Houston and Dallas as the company's next stops. Dallas, where Cruise is currently undergoing testing, will roll out its service by the end of the year.

As of today, October 12, Houstonians in the Downtown, Midtown, East Downtown, Montrose, Hyde Park, and River Oaks neighborhoods can hail a ride from an autonomous electric vehicle seven days a week between the hours of 9 pm to 6 am.

"We believe that everyone has a right to safer, more accessible and more affordable transportation, and we remain focused on cities first because that’s where our mission will have the greatest impact. Houston follows that city-first strategy with its densely traversed downtown, propensity for ridehail, and vibrant cultural center," Sola Lawal, Cruise's Houston manager, tells InnovationMap. "Cruise also shares in Houston’s Vision Zero mission to end traffic deaths and serious injuries by 2030 and we’re excited to address the transportation needs of Houston communities."

Although today marks the launch to the public, Cruise's employees and their friends and family have been testing out the service since August.

"People love this shift from working for your car as the driver, to the car working for you and the time this gives people back in their days," he explains. "A common reaction from first time riders starts with people being shocked and awed for the first two minutes then the ride becomes so normal that you forget you're in a driverless car."

Founded in 2013 by CEO, CTO, and President Kyle Vogt and Chief Product Officer Dan Kan, Cruise vehicles have self-driven over 5 million miles — 1 million of those miles were cruised on Texas streets. The company's fleet includes 400 electric vehicles powered by renewable energy.

Cruise's plan for Houston is to launch and grow from there, including launching larger passenger vehicles, the Origin fleet, for bigger groups of people.

"We always start small and methodically expand from there. For us it’s all about safety and how we expand in partnership with communities, so we let that be our guide for expansion vs arbitrary timelines," Lawal says. "Our goal is to continue to expand as quickly and safely as possible so we can get folks to the Rodeo when it starts and back home, anywhere in Houston, when it ends. You can expect expanded map areas, increased supply of AVs, and expanded hours until we are 24/7 across Houston."

Cruise has raised $10 billion in capital commitments from investors, including General Motors, Honda, Microsoft, T. Rowe Price, Walmart, and others. Additionally, the tech company has also a $5 billion credit line with GM Financial, giving it the financial support needed to scale. Strategically aligned with General Motors and Honda, Cruise has fully integrated manufacturing at scale.

Cruise, which touts a pricing model competitive to existing rideshares, is launching with $5 flat-rate rides for passengers.

"Houstonians who ride with us have the chance to be part of history in the making," Lawal tells Houston's to-be Cruise riders. "The industry has made incredible progress in the last two years but we are still in the early days of what’s to come as driverless ridehail becomes a reality for more people.

"We are proud of the service we’ve built so far and the safety record we have to show for it, but will always continue to improve. We're excited to launch with the community of Houston and we simply ask that you give it a try," he continues. "And when you do please give us feedback, we’d love to hear about your experience."

Origin, a larger, six-person self-driving vehicle, will also launch in the Houston market once Cruise rolls it out. Rendering courtesy of Cruise

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”